Sperm Epigenome in Hodgkin Lymphoma

Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors. We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.

NCT Number	NCT07449832
Lead Sponsor	Rennes University Hospital Collaborators: Institut National de la Recherche Scientifique - Centre Armand Frappier Santé Biotechnologie
Conditions	Hodgkin Disease Lymphoma
Enrollment	50 participants
Start Date	2026-06-01
Primary Completion	2030-01-01 (estimated)
Study Completion	2030-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-14